Regulus Reports Third Quarter 2016 Financial Results

Go back to Regulus Reports Third Quarter 2016 Financial Results

Cowen Downgrades Regulus Therapeutics (RGLS) to Market Perform

November 2, 2016 7:10 AM EDT

Cowen downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.

Shares of Regulus Therapeutics closed at $2.80 yesterday.

... More